EGFR-mutated lung cancer: a paradigm of molecular oncology by Zhang, Zhenfeng et al.
www.impactjournals.com/oncotarget/  Oncotarget, November, Vol.1, No 7
Oncotarget 2010; 1:  497 - 514 www.impactjournals.com/oncotarget 497
EGFR-mutated lung cancer: a paradigm of molecular oncology
Zhenfeng Zhang1, Amy L. Stiegler2, Titus J. Boggon2, Susumu Kobayashi3, and 
Balazs Halmos1
1 Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center, New York Presbyterian Hospital- Columbia 
University Medical Center, New York, NY, USA
2 Department of Pharmacology, Yale School of Medicine, New Haven, CT, USA
3 Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Correspondence to: Balazs Halmos, e-mail: bh2376@columbia.edu
Keywords:  EGFR, tyrosine kinase, lung cancer, therapy, oncology
Received: September 30, 2010, Accepted: October 25, 2010, Published: October 25, 2010
Copyright: © Zhang et al.  This is an open-access article distributed under the terms of the Creative Commons Attribution License, which 
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 
AbstrAct:
The development of EGFR tyrosine kinase inhibitors for clinical use in non-small cell 
lung cancer and the subsequent discovery of activating EGFR mutations have led 
to an explosion of knowledge in the fields of EGFR biology, targeted therapeutics 
and lung cancer research. EGFR-mutated adenocarcinoma of the lung has clearly 
emerged as a unique clinical entity necessitating the routine introduction of molecular 
diagnostics into our current diagnostic algorithms and leading to the evidence-based 
preferential usage of EGFR-targeted agents for patients with EGFR-mutant lung 
cancers. This review will summarize our current understanding of the functional 
role of activating mutations, key downstream signaling pathways and regulatory 
mechanisms, pivotal primary and acquired resistance mechanisms, structure-
function relationships and ultimately the incorporation of molecular diagnostics and 
small molecule EGFR tyrosine kinase inhibitors into our current treatment paradigms.
AbbreviAtions Used:
EGFR- epidermal growth factor receptor  NSCLC – non-small cell lung cancer
TKI- tyrosine kinase inhibitor    PFS- progression-free survival
OS- overall survival    HR- hazard ratio
RR- response rate    ORR- overall response rate
BSC- best supportive care    CR- complete remission
Her fAmily/eGfr- bAckGroUnd/
role in cAncer
The epidermal growth factor receptor (EGFR) 
family, a member of the subclass I of the transmembrane 
receptor tyrosine kinase superfamily, consists of four 
closely related members: EGFR/ERBB1/HER1, ERBB2/
HER2, ERBB3/HER3, and ERBB4/HER4 [1]. The 
founder member, EGFR was first identified as a 170-kDa 
protein on the membrane of A431 epidermoid cells and 
other  ERBB  members  were  identified  by  screening  of 
cDNA libraries for EGFR related molecules [2,3]. These 
receptors are normally expressed in various tissues of 
epithelial, mesenchymal, and neural origin. The crucial 
roles of the EGFR family proteins are supported by a 
series of knockout mouse studies. Mice lacking EGFR 
die between day 11.5 of gestation and day 20 after birth, 
depending on their genetic backgrounds [4]. Analyses 
of the knockout mice reveal placental defects and lung 
immaturity, both of which can be the causes of death. 
They also show abnormalities in the bone, brain, heart, 
and various epithelial organs such as gastrointestinal 
tract, skin, hair follicles and eyes [4]. Detailed analyses 
show that deletion of EGFR leads to impaired branching 
and deficient alveolization and septation in lungs [5]. In 
addition, type II pneumocytes are immature, and there is a 
lack of response in up-regulation of surfactant protein C in 
mice lacking EGFR [5]. Mice lacking ERBB2 , ERBB3, or 
ERBB4 are embryonic lethal and have defects in cardiac Oncotarget 2010; 1:  497 - 514 498 www.impactjournals.com/oncotarget
and neuronal development [4]. In mammals, eleven growth 
factors bind to the ERBB receptors: EGF, transforming 
growth factor α (TGFα), heparin-binding EGF-like growth 
factor, amphiregulin, beta-cellulin, epiregulin, epigen, and 
neuregulin1-4, of which seven are ligands of EGFR [6,7]. 
Upon binding, the ERBB receptors form homo- or hetero-
dimers, resulting in autophosphorylation of the receptors. 
Of note, mice lacking EGF show no overt phenotype 
[8]. Mice lacking TGFα show hair follicle, skin, and eye 
abnormalities, however, they are viable and fertile [9,10]. 
These observations indicate that there is a high level of 
redundancy among ligands. 
Given the pivotal roles of the ERBB receptors in 
normal development, one can imagine that dysregulation 
of these genes or proteins can lead to tumorigenesis. 
Indeed, EGFR is overexpressed in a variety of human 
cancers including lung, head and neck, colon, pancreas, 
breast, ovary, bladder and kidney, and gliomas 
[11,12]. More than 60% of non-small cell lung cancers 
(NSCLCs)  show  EGFR  overexpression,  whereas  no 
overexpression is detected in small cell lung cancer [13]. 
The overexpression of EGFR is presumably caused by 
multiple epigenetic mechanisms, gene amplification, and 
oncogenic viruses [11]. It has been shown that EGFR 
expression is associated with poor prognosis [14]. In 
addition to EGFRs themselves, the EGFR ligands may 
also play an important role in lung tumorigenesis. EGF, 
TGFα, and amphiregulin are expressed in NSCLCs, and 
activate EGFR and its downstream signaling pathways 
by autocrine loops [15]. In addition, a distinct ligand for 
ERBB3 and ERBB4, called neuregulin-1 is overexpressed 
in NSCLC [15].
eGfr mUtAtions- discovery/ 
biocHemistry
The EGFR protien consists of three regions: 
an  extracellular  ligand-binding  region,  a  single 
transmembrane helix region, and a cytoplasmic region. The 
tyrosine kinase domain accounts for approximately 50% 
of the cytoplasmic region, with the remainder composed 
of the 38 amino acid cytoplasmic juxtamembrane (JM) 
region and the 225 amino acid carboxyl terminal (CT) 
region [16]. As shown in Figure 1, mutations in the EGFR 
gene cluster in specific areas, suggesting that these areas 
are crucial for receptor function or regulation.
mutations in the extracellular region
It has been shown that there are three major types of 
deletion mutations in the extracellular region depending 
on the site and length of deletions: EGFR vI, EGFR 
vII, and EGFR vIII. They were originally discovered in 
gliomas [17]. Of these mutant forms, EGFR vIII is the 
most  common  mutation  in  gliomas  (30-50%)  and  has 
been extensively studied since its discovery in 1990 [3]. 
This mutant lacks a large part of the extracellular portion 
including the ligand-binding region, leading to constitutive 
dimerization and activation of the receptor. This mutation 
is detected in 5% of lung squamous cell carcinomas, but 
not in other non-small cell histologies [18]. In addition to 
the deletions, novel missense mutations in the extracellular 
domain have been reported in 13.6% in glioblastomas; 
however, these point mutations have not been found in 
lung tumors with any frequency [19].
mutations in the juxtamembrane region
A recent study revealed that there is a domain in the 
EGFR juxtamembrane region that plays an activating role. 
This JM activating domain seems to enhance formation 
of the asymmetric dimer, thereby promoting allosteric 
activation of the acceptor kinase domain (see “Structural 
Implicatons”  section  below).  Several  rare  mutations  in 
this  domain  have  been  identified  in  NSCLC  patients. 
Two of these missense mutants, V689M and L703F are 
constitutively  active,  possibly  because  they  stabilize 
acceptor/donor interactions [16].  
mutations in the kinase domain
A tandem kinase duplication in the tyrosine kinase 
domain has been described in glioblastomas. This mutant 
is constitutively active and confers tumorigenicity [20]. 
In lung cancer, a series of mutations in the kinase domain 
was originally identified in correlation with sensitivity to 
EGFR inhibitors. Two anilinoquinazoline EGFR tyrosine 
kinase  inhibitors  (TKIs),  gefitinib  and  erlotinib,  were 
approved for use in unselected patients with NSCLC in the 
2nd and 3rd line setting after failure of first line platinum-
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figure 1: oncogenic eGfr variants. Cartoon  shows  the 
positions of key EGFR mutations/variants in the corresponding 
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based chemotherapy in 2003 and 2004, respectively in the 
United States [21] and some patients were noted to have 
major and sometimes durable responses [22]. The selective 
response of a fraction of NSCLC to these agents can be 
explained by somatic mutations in the tyrosine kinase 
domain of EGFR in most patients with NSCLC responsive 
to gefitinib or erlotinib [23-25]. EGFR mutations are more 
common in NSCLC from tumors with adenocarcinoma 
histology, women, Asians, and never smokers with 
widely varying frequencies dependent on the population 
examined [26-28]. EGFR mutations are rarely found in 
squamous cell carcinomas of the lung, small cell lung 
cancer or other epithelial malignancies. Thus, activating 
somatic EGFR mutations are a unique feature of a sub-
class of NSCLC. The most prevalent EGFR mutations 
consist of small inframe deletions around the conserved 
LREA motif of exon 19 (residues 747-750) and a point 
mutation (L858R) in exon 21 [21], which account for more 
than 90% of all EGFR kinase mutations. Oncogenecity 
of  the  exon  19  deletion  and  the  L858R  mutation  has 
been  shown  in  inducible  mouse  models  [29,30].  Point 
mutations in exon 18, predominantly at G719 account for 
approximately another 5% of EGFR mutations [15]. In-
frame insertions and point mutations in exon 20 account 
for  5%  of  the  mutations,  which  are  rather  insensitive 
to reversible EGFR inhibitors but might be sensitive 
to  irreversible  EGFR  inhibitors,  such  as  CL-387,785 
[15,31]. These EGFR mutations activate the EGFR 
signaling  pathway  and  promote  EGFR-mediated  pro-
survival and anti-apoptotic signals through down-stream 
targets as discussed below. In contrast to the activating 
mutations  above,  a  secondary  mutation  was  identified 
as a single base pair change leading to a threonine to 
methionine (T790M) amino acid alteration in exon 20 as 
a mechanism of acquired resistance to EGFR inhibitors. 
It accounts for more than 50% of primarily EGFR TKI-
sensitive lung tumors which become resistant to EGFR 
inhibitors[32,33]. Other resistance mutations in exon 19, 
such as D761Y and L747S, have been reported [34,35]; 
however, these mutations seem to be rare. These EGFR 
kinase domain mutations and other kinase mutations such 
as K-RAS mutations usually exhibit a mutually exclusive 
pattern  in  NSCLC,  suggesting  that  the  EGFR  kinase 
mutations per se are responsible for initiating tumors.
In gliomas, two forms of deletion mutants in the 
carboxyl terminal region have been reported. EGFR vIV 
harbors an in-frame deletion and EGFR vV has a carboxyl 
terminal truncation [17](Fig. 1). These mutants seem to 
be constitutively active: computational analyses suggest 
that this is due to the fact that the deleted region has an 
inhibitory effect on kinase activity [36]. However, these 
mutants have not been reported in lung cancer.
oncoGenic eGfr siGnAlinG- key 
downstreAm pAtHwAys/ tArGets
Upon binding of natural ligands (e.g., EGF, TGFα, 
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figure 2: key mediators downstream of eGfr signaling pathway in lung cancer. EGFR dimerization results in autophosphorylation, 
kinase activation, and subsequent activation of three major signaling pathways,including RAS/RAF/MEK/ERK1/2, PI3K/AKT and STATs 
pathways. BIM is significantly induced to exhibit pro-apoptotic functions upon EGFR inhibition via mostly ERK regulation in NSCLC cells. 
Cyclin D1 is greatly suppressed by EGFR inhibition, promoting cell cycle arrest. ERK1/2 signalling is typically negatively regulated by a 
family of dual-specific MAPK phosphatases, known as DUSPs or MKPs, especially DUSP1, DUSP4, and DUSP6 in NSCLC. DUSP1 and 
DUSP4 function to terminate ERK signaling in nucleus whereas DUSP6 inhibits ERK activation in the cytoplasm. Oncotarget 2010; 1:  497 - 514 500 www.impactjournals.com/oncotarget
and multiple other ligands) to its extracellular domain, 
EGFR forms dimers with itself and other members of the 
ErbB family via specific dimerization domains [37,38], 
which induces conformational shifts that promote tyrosine 
autophosphorylation in the activation loop of EGFR and 
consequent  kinase  activation  leading  to  stimulation  of 
intracellular  signaling  cascades  such  as  the  RAS/RAF/
ERK, PI3K/Akt, and STAT signaling pathways (Fig. 2). 
The EGFR family mediated signaling pathways have 
been shown to be important for proper regulation of many 
developmental, metabolic, and physiologic processes 
mediated by EGF, TGFα, and multiple other ligands. In 
numerous cancers, including glioblastomas, colon cancer, 
breast cancer, and non-small cell lung cancer, the output 
of the EGFR pathway is commonly increased by genetic 
mutation and overexpression of the receptor, overactivity 
of its ligands or cofactors and less commonly reduced 
inhibition through loss of its negative regulatory pathways 
driving the mitogenic, antiapoptotic, angiogenic and pro-
invasive  behaviour  of  the  cancer  cells.  EGFR-targeted 
drugs including tyrosine kinase inhibitors, such as erlotinib 
and gefitinib, are primarily used in lung cancer treatment 
producing significant clinical responses in 10% to 30% 
of all NSCLC patients [32,39,40] and currently used as 
first line therapy for lung cancers with EGFR mutations 
achieving about 70% response rates [41,42]. Humanized 
monoclonal antibodies against the extracellular structure 
of EGFR such as cetuximab and panitumumab, are 
primarily used in colorectal cancer and head/neck cancer 
[43] and will not be further discussed in this review. 
Inhibition of key signalling mediators downstream of 
EGFR should also lead to clinical effects in the treatment 
of lung cancer with robust EGFR activity. Therefore, 
identification  and  understanding  critical  downstream 
effectors of oncogenic EGFR variants should help to 
develop new treatment targets and in fact, a large number 
of pharmacological inhibitors against those key mediators 
are under intensive basic and clinical investigations as 
summarized  below.  The  pivotal  ERK1/2-MAPK  and 
PI3K/AKT  pathways  play  critical  roles  in  gefitinib/
erlotinib-induced antitumor effects in NSCLC cell lines 
and tumors with EGFR addiction [44,45]. However, 
inhibitors directly targeting ERK1/2 or PI3K/AKT have 
not been evaluated carefully in clinic yet.
 mtor
mTOR is an important downstream effector of the 
PI3K/AKT  signalling  pathway  and  mTOR  inhibitors 
can effectively block growth and survival signals by 
inactivating downstream effectors such as p70S6K and 
4E-binding protein 1 [46]. mTOR represents an attractive 
target because its inhibition could allow avoidance of 
possible side effects associated with inhibition of upstream 
PI3K/AKT signaling molecules with broader biological 
functions, including those involved in glucose signaling 
[47]. 
bim
Bim,  a  proapoptotic  BH3-only  Bcl-2  family 
polypeptide  and  also  known  as  BCL2-like  11,  has 
been shown to be a key downstream effector of EGFR 
signalling by several groups [35,48,49]. Bim expression 
was  significantly  induced  by  EGFR  TKI  inhibition  in 
gefitinib-sensitive EGFR-mutant lung cancer cells through 
both  transcriptional  and  post-translational  mechanisms. 
Knockdown of Bim by small interfering RNA was able to 
attenuate apoptosis induced by EGFR TKIs, and addition 
of a BH3 mimetic enhanced gefitinib-induced apoptosis, 
suggesting that inducing Bim or use of BH3 mimetics 
may give rise to similar effects to inhibition of EGFR by 
promoting apoptosis and even overcoming EGFR TKI 
treatment resistance in lung cancer. 
cyclin d1
Cyclin D1 forms a complex with and functions as 
a regulatory subunit of CDK4 or CDK6, whose activity 
is required for cell cycle G1/S transition. Cyclin D1 has 
been identified as a key downstream effector of EGFR 
signalling by using microarray transcriptional profiling of 
gefitinib-resistant NSCLC EGFR L858R-T790M mutant 
H1975 cells exposed to the irreversible and in these cells 
still  effective  inhibitor,  CL-387,785  versus  gefitinib. 
Cyclin D1 was highly suppressed by CL-387,785 but not 
by  gefitinib  and  downregulation  of  cyclin  D1  resulted 
in suppression of E2F-responsive genes, consistent with 
proliferation  arrest.  EGFR-mutant  NSCLC  cells  have 
higher expression of cyclin D1 than cells with wild-type 
EGFR and are sensitive to the cyclin-dependent kinase 
inhibitor  flavopiridol  [50].  Cyclin  D1  has  also  been 
introduced as an important biomarker among EGFR, 
K-RAS and VEGFR in the BATTLE trial focusing on 
personalized therapy for lung cancer [51]. 
Dual-specificity phosphatases
MAPK signalling is negatively regulated by a family 
of dual-specificity MAPK phosphatases, known as DUSPs 
or  MKPs  [52].  A  nuclear-inducible  DUSP1  has  been 
reported to be a critical downstream effector of EGFR 
inhibition  by  AG1478  in  PC9  cells.  Downregulation 
of  DUSP1  correlated  with  AG1478-induced  apoptosis 
in  PC9  cells  via  activation  of  JNK  kinase  activity, 
whereas overexpression of DUSP1 led to resistance to 
AG1478  of  PC9  cells  [53].  DUSP4  and  DUSP6  have 
been well described as transcriptional targets of EGFR-
ERK1/2 signalling and demonstrated as novel tumor 
growth suppressors in NSCLC [45,50,54]. In particular, Oncotarget 2010; 1:  497 - 514 501 www.impactjournals.com/oncotarget
genetically  mediated  loss  of  DUSP4  correlates  closely 
with EGFR mutations suggestive of the cooperative nature 
of the two independent events. Due to their functional 
negative feedback roles in regulation of MAPKs, many 
DUSP family members may serve as potential targets for 
lung cancer therapy.
other targets
Some  signalling  pathways  transduced  by  receptor 
tyrosine kinases other than EGFR may also play important 
roles  in  EGFR-addicted  NSCLC  and  could  serve  as 
targets for therapeutic purpose. Recent studies have 
demonstrated close crosstalk between EGFR and MET 
[55]. Aberrant EGFR hyperactivation results in increased 
MET expression in EGFR-mutant NSCLC cells via HIF-
1α activation but EGFR TKI resistance-rendering MET 
amplification could uncouple MET levels from the EGFR 
signalling pathway [56]. MET has been shown to be a 
key downstream mediator of EGFR-induced invasiveness 
in  EGFR-dependent  NSCLC  cells,  suggesting  that 
therapeutic inhibition of MET in combination with EGFR 
blockade may prevent tumor metastasis beyond the effect 
of EGFR alone in a subset of lung cancers, in addition 
to the potential benefit of preventing the emergence of 
resistance through MET amplification [57]. 
primAry And secondAry eGfr 
resistAnce
Primary and acquired drug resistances are key issues 
in the area of targeted therapeutics. Despite overexpression 
of EGFR in the majority of lung tumors, only a small 
fraction  of  patients  responds  significantly  to  EGFR 
inhibition and the majority of tumors demonstrate primary 
resistance. Activating mutations of EGFR correlate with 
exquisite sensitivity to growth inhibition by erlotinib or 
gefitinib,  but  patients  ultimately  develop  progressive 
disease after a typical period of 6-12 months indicating 
the development of resistance to these agents [58]. 
primAry resistAnce
Primary resistance affects patients who are initially 
refractory to EGFR tyrosine kinase inhibitor treatment. 
Certain molecular factors have been identified as predictive 
of EGFR TKI response in lung cancers, such as increased 
EGFR gene copy number and activating mutations within 
the EGFR TK domain [30,59,60]. Thus, patients without 
these characteristics are more likely to present with 
primary resistance to EGFR TKIs. The recent IPASS study 
reported that Asian NSCLC patients containing wild-type 
EGFR had a shorter time to progression to EGFR TKIs as 
compared to the outcome of patients treated with classical 
chemotherapy and a very low response rate of 2% [41], 
suggesting that genetic wild-type of EGFR by and large 
confers primary resistance to EGFR TKIs. 
resistant eGfr mutants
Multiple EGFR mutations have also been implicated 
in primary resistance to EGFR TKIs, such as the presence 
of insertion mutations in exon 20 of EGFR that precludes 
the binding of gefitinib or erlotinib to the EGFR TK domain 
conferring resistance [61]. Somatic exon 20 insertions are 
also detected in ErbB2 in NSCLC and similarly appear 
to confer resistance to gefitinib or erlotinib [61]. Even 
though the exon 20 insertions represent less than 5% of 
all known mutations in the EGFR gene, strategies aimed 
at overcoming resistance induced by exon 20 insertions of 
EGFR and ErbB2 have been studied by use of irreversible 
inhibitors of EGFR and ERBB2 as well as heat shock 
protein-90  inhibitors,  in  that  interaction  with  HSP-90 
seems to be required for stability of mutated EGFR and 
ErbB2  and  HSP-90  inhibitors  promote  mutated  EGFR 
degradation [62,63]. 
k-rAs
K-RAS  belongs  to  the  RAS  family  of  oncogenes 
and accounts for more than 90% of RAS mutations in 
NSCLC. K-RAS mutations have been detected in 15-30% 
of NSCLC, with the majority occurring in codons 12 and 
13, in particular codon 12 (>90%). The mutations lead 
to impaired GTPase activity and subsequent constitutive 
activation  of  RAS  signaling,  which  is  downstream 
of EGFR leading to activation of proliferative and 
anti-apoptotic  pathways  such  as  the  ERK  signaling 
pathway. K-RAS mutations have been demonstrated to 
be  significantly  associated  with  primary  resistance  to 
EGFR-TKIs in a wide variety of tumor types including 
lung  cancer  [64-67].  K-RAS  mutations  present  more 
commonly in adenocarcinomas from elderly patients 
and heavy smokers who have been identified as a group 
unlikely  to  respond  to  EGFR TKIs  [68].  Development 
of effective K-RAS inhibitors remains one of the most 
daunting challenges for current tumor therapeutics. 
other mechanisms
Other less clearly validated markers for primary 
resistance to EGFR TKIs include loss of PTEN, BRAF 
mutations,  increased  expression  of  MAPK,  ABCG2, 
IGFR1,  and  BCL-2,  and  angiogenesis  regulators  [69]. 
Expression level of steroid receptor coactivator-3 (SRC-
3) has recently been shown to inversely correlate with 
resistance to gefitinib or erlotinib in 48 NSCLC cell lines 
using the reverse-phase protein array technique, whereas 
high SRC-3 protein level correlates with resistance to the Oncotarget 2010; 1:  497 - 514 502 www.impactjournals.com/oncotarget
TKIs  [70]. ALK  translocations  represented  by  EML4-
ALK fusion are found to be mutually exclusive with EGFR 
or  K-Ras  mutations  and  predict  for  primary  resistance 
to EGFR TKIs in patients with advanced NSCLC since 
EGFR output is not key to cell survival in these tumors 
[71]. An emerging concept about cancer stem cell (CSC) 
or cancer-initiating cells has been proposed as a potential 
mechanism  of  primary  drug-resistance  [72].  Signalling 
pathways  involving  TGF-β,  Wnt,  Notch,  Hedgehog, 
PI3K/PTEN/mTOR,  IGF-1R,  histone  demethylase,  and 
histone deacetylase (HDAC) have been implicated in CSC 
self-renewal,  maintenance,  and  plasticity  [72,73].  It  is 
postulated that any strategy aimed at killing the abundant 
non-stem cancer cells will fail without eradicating the few 
CSCs in a tumor. These cancer stem cells might be less 
dependent on growth pathways, such as the EGFR pathway 
and might survive drug inhibition. Acquired resistance is 
indeed hypothesized by some to emerge in this quiescent 
stem  cell  population  over  time  by  the  acquisition  of 
secondary mutations for example. Potentially those key 
regulators involved in the CSC programming may act as 
effective targets for drug development to overcome the 
primary resistance to anticancer drugs including resistance 
to EGFR-targeted therapy in lung cancer. 
AcqUired resistAnce
Acquired resistance generally affects patients who 
initially respond to treatment but subsequently experience 
a loss of response [74]. As EGFR TKIs are now proven 
as  standard  first-line  therapy  for  NSCLC  patients  with 
EGFR mutations [41,42], a rapidly growing number of 
patients  with  acquired  resistance  will  be  encountered. 
Accordingly, a clinical definition of acquired resistance to 
EGFR TKIs has been established for unifying therapy and 
studying this subset of lung cancer [75].
secondary eGfr mutations
The acquisition of resistance to the targeted inhibition 
of  kinases  in  cancer  is  by  now  a  well-documented 
phenomenon in several cancer types. Although the 
importance of the cancer stem cell is firmly established 
for  primary  drug  resistance,  the  etiology  of  acquired 
resistance is still the subject of some debate. As compared 
to the large number of secondary resistance mutations 
noted in acquired imatinib resistance in CML, in the case 
of EGFR-TK, there are currently only several documented 
resistance  point  mutations  to  gefitinib  and  erlotinib, 
including T790M [32,33], L747S [35] and D761Y [34]. 
The T790M point mutation in the EGFR kinase domain 
has been reported to be the most common secondary 
resistance mutation, accounting for about 50% of tumors 
relapsed from prior TKI therapy [33]. The T790M mutation 
results in alteration of the topology of the ATP-binding 
pocket not only interrupting the physicochemical binding 
of gefitinib/erlotinib, but also leading to much increased 
affinity of the EGFR protein to ATP resulting in resistance 
to EGFR-TKIs [76]. Resistance to the T790M mutation 
in lung cancer could be overcome in vitro by irreversible 
EGFR small molecule inhibitors such as CL-387,785 [77] 
and BIBW2992 [78], Hsp90 inhibition [79], combination 
of  multiple  RTK  inhibitor  and  mTOR  inhibitor  [80], 
combination  of  TS-targeting  drugs  (5-fluorouracil  or 
pemetrexed)  and  BIBW2992  [81],  and  novel  mutant-
selective EGFR kinase inhibitors [82]. 
MET amplification
The second major mechanism of acquired resistance 
reported is the amplification of the MET oncogene that 
activates  ERBB3/PI3K/AKT  signalling  in  lung  cancer 
[57]. MET amplification was found in 4 of 18 lung cancer 
biopsy  samples  obtained  from  patients  with  acquired 
resistance to gefitinib or erlotinib [57]. Preclinical data 
suggests that combination of EGFR and MET TKIs can 
be a treatment strategy for EGFR mutated NSCLC either 
delaying acquired resistance or for the treatment of tumors 
with  co-existing  EGFR  activating  mutations  and  MET 
amplification [83,84]. 
other mechanisms
Given  that  T790M  and  MET  amplification 
collectively  account  for  approximately  60%  of  the 
acquired  resistance  cases,  there  are  clearly  additional 
mechanisms that underlie resistance to EGFR TKIs. 
Other mechanisms that have been implicated in acquired 
resistance include overexpression of AXL tyrosine kinase 
receptor [85], altered EGFR trafficking [86], expression of 
insulin-like growth factor-1 [87], amplification of mutant 
EGFR or hyperactivation of components of downstream 
signaling pathways [88], and expression of the ABCG2 
drug-efflux transporter [89]. Recently, it has been shown 
that activation of TGF-β/IL-6 signaling leads to epithelial-
to-mesenchymal transition and erlotinib resistance [90]. 
Targeting  key  EGFR-downstream  signalling  pathways 
should be an alternative approach for overcoming 
resistance to erlotinib or gefitinib in lung cancers. For 
example, the mTOR inhibitor, everolimus, has been shown 
to reduce the expression of EGFR signalling effectors and 
cooperates with gefitinib to overcome resistance [91], and 
the combination of an mTOR inhibitor and an irreversible 
EGFR inhibitor may be an effective strategy to overcome 
EGFR TKI resistance.
strUctUrAl implicAtions of 
eGfr ActivAtion/ strUctUrAl 
conseqUences of oncoGenic eGfr Oncotarget 2010; 1:  497 - 514 503 www.impactjournals.com/oncotarget
mUtAtions
eGfr activation
Normal  regulation  of  EGFR  family  receptor 
tyrosine kinases comprises a precise orchestration of 
interconnecting  components.  Acquired  mutations  (Fig. 
1), even of single amino acids, can deleteriously alter 
the  choreography  of  regulation;  however,  it  is  these 
acquired mutations that provide a therapeutic entry-point 
for targeted inhibition of dysregulated EGFR signaling. 
Regulation of EGFR family signal transduction is one of 
the most comprehensively studied of the receptor tyrosine 
kinase family at the atomic-level, and current structural 
studies are still providing surprising and exciting new 
information  about  their  regulation.  Principal  among 
these recent findings is the discovery that an asymmetric 
homodimer assembly is critical for kinase activation. 
This, alongside studies investigating the structures of 
activating and resistance mutations in the kinase domain 
itself, has recently provided a far clearer understanding of 
the mechanisms of EGFR family activation and resistance 
to small molecule inhibitors. 
The catalytic portion of the EGFR family comprises 
a cytoplasmic domain with a protein kinase fold. This fold 
generally  functions  to  catalyze  phosphotransfer  of  the 
ATP γ-phosphate to target protein substrates primarily on 
tyrosine, serine and threonine residues. The protein kinase 
fold is a bi-lobed domain that includes a C-terminal lobe 
rich in alpha-helices and an N-terminal lobe that consists 
mainly of beta-strands. In the transition between inactive 
and active states for protein kinases, conformational 
changes  usually  occur  in  the  N-terminal  lobe  that 
reposition the catalytic residues to the correct spatial 
locations  that  favor  phosphotransfer.  Conformational 
changes associated with activation also often occur within 
a short region of the kinase domain termed the activation 
segment. Autoinhibitory conformations of protein kinases 
are well described by structural biology studies and 
have proven to be diverse among the family; however, 
the spatial orientation of residues required for catalytic 
competency is very well conserved. While the structural 
diversity of inactive states among protein kinases provides 
well-documented therapeutic targets (imatinib targets an 
inactive conformation of BCR-Abl), structural similarities 
in kinase active state conformations can lead to difficulties 
in achieving specificity in kinase-targeted drug discovery. 
In a general sense, the acquisition of transforming point 
mutations for this class of proteins disrupts the normal 
active-inactive balance to favor the active state.
In the EGFR family of receptor tyrosine kinases, 
the  specific  mechanisms  of  normal  kinase  regulation 
are  now  well-defined  by  structural  biology  techniques 
[92,93]. Extracellular conformational rearrangement 
upon ligand (e.g. EGF) binding allows dimerization of 
the receptor, the consequence of which is the ability of 
the  cytoplasmic  kinase  domains  to  trans-activate  (Fig. 
3). Activated EGFR kinase is able to autophosphorylate 
the C-terminal tail, thereby creating recruitment sites for 
phosphotyrosine-binding domains of downstream proteins 
in EGFR signaling cascades. Until recently the atomic-
level  mechanisms  of  EGFR  trans-activation  were  not 
INACTIVE ACTIVE
EGF
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DONOR
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N C
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figure 3.  schematic diagram of eGfr activation. Shown for EGFR are the four domains in the extracellular region, transmembrane helix, 
and the cytoplasmic juxtamembrane region and tyrosine kinase domain. In the absence of ligand, the EGFR resides on the cell surface in an 
inactive/autoinhibited conformation (left). Upon ligand (EGF) binding, the autoinhibitive conformation in the EGFR ectodomain is released, 
leading to ectodomain-mediated receptor dimerization (right). In the cytoplasm, receptor dimerization results in formation of an asymmetric 
kinase homodimer in which the C-terminal lobe of the “donor” kinase (colored pink) interacts with the N-terminal lobe of the acceptor/
activated kinase (colored green) to confer allosteric activation of the acceptor kinase. The juxtamembrane segment of the acceptor kinase in 
turn associates with the C-terminal lobe of the donor kinase to stabilize this activating asymmetric dimer (right zoom).Oncotarget 2010; 1:  497 - 514 504 www.impactjournals.com/oncotarget
known; however, analysis of the crystal packing within 
previous EGFR kinase domain crystal structures led to 
the observation that in the active state the N-terminal lobe 
of the EGFR kinase domain interacts with the C-terminal 
lobe  of  a  partner  kinase  domain  [94].  Subsequent 
studies have validated this tail-head, or donor-acceptor, 
interaction and discovered that the donor, or tail, molecule 
activates the acceptor, or head, molecule by inducing 
an activating conformational movement centered on the 
N-terminal lobe [95,96]. The result is that only one of the 
kinase  domains  in  an  activated  EGFR-family  receptor 
complex is in a catalytically competent state, a finding 
that helps explain the mechanism of ErbB2 activation by 
the catalytically inactive ErbB3 via heterodimerization. 
Further studies have shown that the juxtamembrane region 
(the segment connecting the transmembrane helix to the 
kinase domain) of the active/acceptor EGFR stabilizes this 
asymmetric dimer by interacting with the C-terminal lobe 
of the donor kinase [16,97]. Acquired point mutations in 
the juxtamembrane region seen in NSCLC (e.g. V689M, 
L703F) further promote the asymmetric head-tail active 
state [16], providing a clear rationale for activated EGFR 
in these patients. 
oncogenic eGfr mutations
Structural studies have also provided clues to the 
mechanisms by which activating and resistance mutations 
alter kinase activity and how small molecule inhibitors 
can  specifically  target  mutant  enzyme  [98].  The  most 
commonly seen activating point mutation in EGFR, 
L858R, is incompatible with the inactive state of the kinase 
[24,99], and the crystal structure of the L858R mutant 
revealed that additional hydrogen bonds are formed which 
serve  to  further  stabilize  the  active  state  of  the  kinase 
[99]. The mechanism by which this and other mutations 
activate EGFR, however, is not completely explained by a 
conformational predisposition to the active-state. Kinetic 
analyses found that clinically relevant mutations in EGFR 
alter binding to both ATP and inhibitors (e.g. erlotinib and 
imatinib) in such a way that the ratio of Kd to Km[ATP] is 
altered in favor of the inhibitors [98-100]. These measured 
changes in apparent Ki therefore provide a mechanism for 
selective inhibition of mutant EGFR by small molecules 
such as erlotinib and imatinib [98]. Alterations in ATP-
dependent reaction rates and inhibitor binding affinities 
are probably the mechanism for acquired resistance by 
the  T790M  mutation  [76].  Therapeutically,  the  use  of 
covalently binding inhibitors (e.g. HKI-272, BIBW2992, 
PF00199804)  may  present  a  mechanism  to  overcome 
resistance by binding in a similar fashion to non-covalent 
inhibitors, but with covalent attachment to EGFR residue 
cysteine-797 [82,98].
tHe clinicAl Use of eGfr-
tArGeted AGents in non-smAll 
cell lUnG cAncer
initial studies
Over the last few years, we have seen a revolution 
in  the  understanding  of  the  appropriate  use  of  EGFR-
targeted  therapy  in  non-small  cell  lung  cancer.  Initial 
studies  of  both  erlotinib  and  gefitinib  demonstrated 
good overall tolerability with skin rashes, diarrhea and 
occasional episodes of pneumonitis noted as the main 
concerns and modest activity of 10-20% response rates 
were noted in unselected populations [101]. Significantly 
higher responsiveness was noted in certain patient subsets, 
such as patients with adenocarcinoma histology, women, 
patients  of  Oriental  descent  and  non-smoking  patients. 
Disappointingly, four large randomized studies combining 
these drugs with upfront chemotherapy demonstrated 
negative results while in the second/third-line setting an 
overall survival benefit was noted in the pivotal BR.21 
study of erlotinib versus best supportive care [102] but 
not  in  the  ISEL  study  comparing  gefitinib  with  best 
supportive care [103], although an overall survival benefit 
in the Asian subset was observed. These studies ultimately 
led to the approval of erlotinib in the U.S. and gefitinib in 
many Asian countries for second-line or subsequent use.
search for predictive biomarkers
Alongside these key clinical studies, multiple 
biomarkers  were  identified  and  tested,  most  notably 
EGFR expression by immunohistochemistry, EGFR copy 
number changes detected by FISH or quantitative PCR 
and with the discovery of activating EGFR mutations 
in highly responsive patients, EGFR mutational status 
[104].  Lately,  it  has  become  quite  clear  that  the  best 
predictor of a major clinical response is the presence 
of activating EGFR mutations in the tumor, mainly 
exon  19  deletions  or  L858R  mutation.  Indeed,  at  this 
point it needs to be recognized that EGFR-mutant lung 
adenocarcinoma is a distinct clinical entity and currently 
upfront general testing for EGFR mutational status 
is endorsed by many leading institutions, is available 
through several commercial entities and with the use of 
multiple platforms ranging from direct sequencing to high 
sensitivity, mutation-specific detection techniques [105]. 
EGFR copy number changes also have some predictive 
value but most of its value might lie in the fact that true 
EGFR gene amplification typically closely correlates with 
EGFR mutational status and thereby is a surrogate marker 
for such. EGFR gene copy number increase (polysomy) 
without EGFR gene amplification is much less robust of Oncotarget 2010; 1:  497 - 514 505 www.impactjournals.com/oncotarget
a predictor. EGFR expression by immunohistochemistry 
has not proven to be a clinically effective predictor of 
responsiveness. Overall, lately there has been a dramatic 
shift in clinical practice towards the isolated use of EGFR 
mutational status when choosing EGFR-targeted therapy 
based on numerous first-line clinical studies listed below. 
Among other biomarkers, serum proteomics have also 
been developed and in a number of studies have shown 
correlation with clinical benefit from EGFR TKI therapy. 
An approved test (VeriStrat) is available for clinical use 
but given other available markers, its clinical utility 
remains somewhat ill-defined [106]. K-RAS mutational 
status repeatedly have been shown to be a negative 
predictor of responsiveness and can be used as a “negative 
surrogate” for EGFR mutational status since by and large 
these mutations are exclusive of each other [65]. 
first-line use
Based on the poor overall outcome and significant 
toxicity of upfront chemotherapy in advanced non-small 
cell lung cancer, EGFR TKI therapy as front-line treatment 
has significant appeal for the appropriate patient. Initial 
studies focusing on leveraged patient populations based 
on clinical predictors of higher EGFR TKI responsiveness 
or selection by EGFR mutational status suggested 
potentially excellent activity with response rates in the 50-
90% range in patients with tumors harboring activating 
EGFR mutations. The American iTARGET trial focused 
on  a  clinically  enriched  population  of  chemo-naïve 
patients with non-squamous histology and demonstrated 
a 55% RR, PFS of 9.2 months and OS of 17.5 months 
in EGFR mutation positive patients [107]. The Spanish 
study group reported the results of a prospective phase 
II study about the use of erlotinib in advanced NSCLC 
patients  harbouring  EGFR  mutations.  2,105  patients 
were  screened  and  350  (16.6%)  identified  to  carry 
EGFR mutations [42]. Median PFS and OS for the 217 
patients who received erlotinib were 14 and 27 months, 
patients with L858R had longer PFS than patients with 
exon 19 deletions and outcomes did not seem to differ 
whether  erlotinib  was  given  in  the  first  or  second-line 
setting.  A  combined  survival  analysis  (I-CAMP)  of 
seven prospective Japanese trials of 148 patients with 
EGFR mutations who received gefitinib demonstrated a 
response rate of 76.4%, median PFS of 9.7 months and 
overall survival of 24.3 months [108]. Good performance 
status and chemotherapy-naïve status were significantly 
associated with a longer progression-free survival. On the 
other hand, overall survival was not affected by first-line 
or second-line gefitinib use suggestive of the benefit to be 
sustained through several lines of therapy.
Recent,  randomized  clinical  studies  have  brought 
further  clarity  to  this  field.  The  IPASS  study  enrolled 
1,217 chemotherapy-naïve patients with advanced lung 
adenocarcinoma with no or light smoking history and 
a PS of 0-2 [41]. Patients were randomized to receive 
gefinitib versus carboplatium/paclitaxel for a maximum 
of  6  cycles.  Gefitinib  demonstrated  superiority  in 
terms of PFS for the ITT population with a HR of 0.74 
(12-months PFS of 24.9 versus 6.7%), however the hazard 
ratio was not constant over time. Further review showed 
dramatic separation of outcomes based on EGFR mutant 
status. In the EGFR-mutant group (59.7% of all patients 
with available test result) the objective response rate of 
71.2% and the PFS of 9.5 months in the gefitinib group 
was much superior to an ORR of 47.3% and PFS of 6.3 
months with chemotherapy compared to a sobering 1.1% 
ORR and a 1.5 month PFS with gefitinib which was much 
worse than results with standard chemotherapy (hazard 
ratio  of  2.85)  in  wild-type  patients. The  results  of  the 
First-SIGNAL  study  comparing  first-line  cisplatinum/
gemcitabine with gefitinib in the first-line treatment of 
309 Asian never-smokers with advanced adenocarcinoma 
similarly showed improved 1-year PFS with gefitinib and 
a response rate of 84.6 versus 37.5% in EGFR mutation 
positive patients while extremely poor results were 
noted  with  gefitinib  in  wild-type  patients  [109]. These 
non-mutant  selective  studies  demonstrated  that  clinical 
factors are less predictive of responsiveness than tumor 
genetics and provide very strong justification for upfront 
testing if first-line EGFR therapy is contemplated since 
clinically selected but EGFR WT patients appear to fare 
dramatically worse on gefitinib than chemotherapy.
Recently, the results of studies exclusively 
focusing  on  EGFR-mutated  adenocarcinoma  have  also 
been  reported.  The  WJTOG3405  study  enrolled  177 
chemotherapy-naïve patients aged 75 years or younger and 
diagnosed with stage IIIB/IV non-small cell lung cancer 
or postoperative recurrence harboring EGFR mutations- 
either exon 19 deletions or L858R [110]. Patients were 
randomly assigned to gefitinib or cisplatinum/docetaxel 
for 3-6 cycles. The gefitinib group had significantly longer 
progression-free  survival  compared  to  chemotherapy 
(9.2  versus  6.3  months).  Myelosuppression,  alopecia, 
fatigue were more common with chemotherapy, while 
skin toxicity, liver dysfunction and diarrhea were more 
frequent  in  the  gefitinib  group.  Two  patients  in  the 
gefitinib group developed interstitial lung disease (2.3%). 
The  NEJ002  study  [111]  was  prematurely  closed  after 
accruing  230  patients  due  to  a  significant  benefit  seen 
for gefitinib versus carboplatinum/paclitaxel in patients 
with  prospectively  identified  EGFR-mutated  advanced 
non-small  cell  lung  cancer.  Analysis  of  the  first  200 
patients  showed  a  doubling  of  PFS  by  gefitinib  (10.8 
vs 5.4 months). Overall response rates were 74% with 
gefitinib and 31% with chemotherapy. Median survival 
was 30.5 months vs 23.6 months with gefitinib versus 
chemotherapy,  the  OS  difference  was  not  statistically 
significant. These results are almost superimposable with 
each other and further demonstrate the excellent activity 
of EGFR TKIs in this setting. Inoue and colleagues [112] Oncotarget 2010; 1:  497 - 514 506 www.impactjournals.com/oncotarget
completed a phase II trial of gefitinib in patients with poor 
PS harboring EGFR mutations and a RR of 66%, PFS 
of 6.5 and OS of 17.8 months were seen demonstrating 
very impressive outcomes in a patient population with a 
generally very poor survival redefining the boundaries of 
when treatment might still be beneficial since patients with 
a PS of >2 are generally not considered to be candidates 
for chemotherapy.
maintenance therapy
In the SATURN trial, 889 patients with advanced 
non-small cell lung cancer and no evidence of disease 
progression after 4 cycles of chemotherapy were 
randomized  to  receive  erlotinib  versus  placebo  until 
progression  or  unacceptable  toxicity  [113].  PFS  (the 
primary endpoint) was prolonged in the erlotinib group 
(HR 0.71) and all biomarker groups showed a PFS benefit 
with erlotinib. In particular, EGFR mutant patients saw 
a  marked  improvement  in  PFS  with  erlotinib  therapy 
(HR 0.10). Median OS was also significantly improved 
for the total population in the erlotinib group (HR 0.81). 
The  survival  benefit  was  particularly  large  in  patients 
with adenocarcinoma histology and was not driven by 
the EGFR-mutation positive subgroup, with a significant 
improvement in survival observed in the EGFR wild-type 
group  ultimately  leading  to  FDA-approval  of  erlotinib 
in this indication. Notably, pemetrexed is also approved 
as  maintenance  therapy  in  advanced  non-squamous 
non-small  cell  lung  cancer  and  bevacizumab  is  also 
utilized in the same setting until disease progression in 
bevacizumab-eligible  patients  based  on  the  survival 
benefit  seen  in  the  ECOG4599  study  confounding  this 
field. Erlotinib certainly appears to be an excellent choice 
in the maintenance setting in patients with EGFR-mutated 
tumors who have not received it as first-line therapy.
second-line therapy 
The pivotal BR.21 study which led to the approval 
of  erlotinib  randomized  731  chemotherapy-refractory 
patients  with  advanced  non-small  cell  lung  cancer  to 
erlotinib or placebo in a 2:1 ratio and a response rate 
of 8.9% was seen in the erlotinib group and an overall 
survival benefit of 6.7 versus 4.7 months was noted [102]. 
ISEL was a randomized, placebo-controlled, international 
multicenter  phase  III  trial  comparing  gefitinib  versus 
BSC as second or third-line treatment for patients with 
advanced  NSCLC.  1,692  patients  were  enrolled  in  a 
ratio of 2:1 to receive gefitinib 250 mg daily or placebo 
plus BSC [103]. Differences in median survival did not 
reach statistical significance while a higher response rate 
and TTP was noted in the gefinitib arm. On preplanned 
subgroup analyses, a longer survival time was seen for 
never-smoker  and  Asian  patients  (9.5  vs  5.5  months) 
treated  with  gefitinib.  Patients  with  EGFR  mutations 
had a higher response rate than wild-type patients (37.5 
vs 2.6%). The INTEREST trial compared gefitinib with 
docetaxel as second or third-line therapy in 1,466 patients 
with  advanced  NSCLC  treated  with  prior  platinum-
based chemotherapy [114]. Median OS was 7.6 months 
in  the  gefitinib  and  8.0  months  in  the  docetaxel  arm 
demonstrating non-inferiority of gefitinib as compared to 
docetaxel. Of note, EGFR mutation positive patients had 
longer PFS and higher RR (42.1 vs 21.1%) and patients 
with high EGFR copy number also had higher RR (13% 
vs 7%) with gefitinib as compared with docetaxel. The 
Korean ISTANA trial compared gefitinib with docetaxel 
as second-line treatment in 161 patients with advanced 
NSCLC and PFS HR (0.729), 6-months PFS (32 vs 13%) 
and RR were found to be improved with gefitinib when 
compared  with  docetaxel  while  OS  was  not  different 
[115].
maintenance beyond progression
Riely and colleagues [116] reported that a subset of 
patients with non-small cell lung cancer who had acquired 
resistance to EGFR TKIs and had discontinued treatment 
progressed rapidly as shown by increased SUV in PET 
scans  at  3  weeks  follow-up  consistent  with  a  disease-
flare associated with reduction of treatment pressure of a 
known biological pathway. This has led to the unproven 
practice of continuing EGFR TKI in primarily EGFR 
TKI-sensitive patients at the time of disease progression. 
This issue has significant implications for clinical practice 
and at least one study is ongoing to answer the question of 
whether this practice is beneficial or not (Table 1).
locally advanced non-small cell lung cancer
With proven benefits of EGFR TKIs in the metastatic 
setting, it would seem logical that such benefits would 
extend to earlier stages of the illness. Nonetheless, the 
SWOG0023  study  surprisingly  demonstrated  inferior 
outcomes  with  maintenance  gefitinib  versus  placebo 
following  definitive  chemoradiotherapy  in  patients 
with locally advanced non-small cell lung cancer [117]. 
Notably, these patients were not selected by biomarker 
status. Few current studies focus on exploring EGFR TKI 
therapy in this setting.
Adjuvant therapy
EGFR  TKIs  provide  mostly  palliative  benefit  in 
the advanced setting similar to the benefit of Herceptin 
in metastatic breast cancer. In patients with resected lung 
cancer, the hope is that this class of drugs would on the 
other hand improve cure rates and studies in this setting Oncotarget 2010; 1:  497 - 514 www.impactjournals.com/oncotarget 507
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are  eagerly  awaited.  The  RADIANT  study  is  a  phase 
III study comparing erlotinib with placebo in resected 
stage IB-IIIA NSCLC patients with EGFR IHC or FISH-
positive tumors with the primary endpoint of improvement 
in DFS. Efficacy data are eagerly awaited, it has been 
reported that 12% of all samples carry EGFR mutations 
and 19% K-Ras mutations [118]. A single-arm adjuvant 
study focusing purely on EGFR-mutated tumors thereby 
examining a more enriched population is also ongoing 
(Table 1).
AcqUired resistAnce
irreversible eGfr inhibitors
The most common acquired resistance mechanism 
is  the  emergence  of  EGFR-T790M,  notable  in  about 
50%  of  EGFR  TKI-responsive  patients  at  the  time  of 
disease progression. Prevention or overcoming resistance 
mediated by EGFR T790M is one of the most important 
and challenging research tasks in this field [58]. While 
in vitro multiple irreversible EGFR inhibitors have been 
noted  to  retain  at  least  partial  efficacy  against  EGFR 
T790M,  initial  experience  with  the  irreversible  dual 
EGFR/ErbB2 TKI, neratinib (HKI-272) was disappointing 
[119]. Another promising irreversible dual EGFR/ErbB2 
inhibitor,  BIBW2992  continues  to  generate  interest. 
Results of the phase II LUX-Lung-2 study focusing on 
patients with EGFR-mutated non-small cell lung cancer 
have been reported and demonstrated a 61% response rate, 
PFS of 14 months and median survival of 2 years [120]. 
Phase III studies of this compound in multiple settings, 
including  following  failure  of  erlotinib  or  gefitinib  are 
ongoing.  PF00299804,  an  irreversible  HER1,  2  and  4 
inhibitor has also shown preliminary anti-tumor activity 
[121] and a predictable safety profile in a phase II study 
in patients with NSCLC after failure of chemotherapy and 
erlotinib. Several responses as well as prolonged stable 
disease  were  reported  in  erlotinib-refractory  patients 
suggestive of potential clinical activity in this subset[122]. 
Further studies of this compound are also ongoing. One 
major concern about these compounds is whether the 
therapeutic window might be too narrow in this setting 
and  side  effects  as  a  result  of  WT  EGFR  or  ErbB2 
inhibition might be limiting. Recently, through a targeted 
chemical screen selective inhibitors against T790M have 
been reported [82] and there is certainly hope that such 
rationally designed compounds might ultimately provide 
sufficient selectivity.
met inhibition
At  least  in  some,  possibly  as  often  as  in  20% 
of  tumors,  acquired  resistance  might  be  mediated 
by  overamplification  of  the  MET  oncogene  rewiring 
oncogenic pathways through overtaking activation of 
the key coupler, ErbB3. Data also suggests that in some 
tumors,  MET-amplified  tumor  cells  might  preexist  and 
ultimately emerge as the predominant clone [83]. These 
data might suggest that combination strategies of EGFR 
and MET inhibition either at the outset to prevent or at 
the time of progression to overcome resistance could be 
promising and multiple clinical studies with a wide range 
of MET-targeted agents are ongoing. At least one study 
has demonstrated prolonged PFS with the combination 
of erlotinib with the MET TKI, ARQ197 as compared to 
erlotinib alone [123] and phase III studies in the EGFR 
TKI-naïve setting are ongoing.
other strategies
Several preclinical reports showed that other agents, 
such  as  the  anti-EGFR  monoclonal  Ab  cetuximab  or 
PI3K/mTOR inhibitors combined with irreversible EGFR 
inhibitors hold promise to overcome resistance mediated 
by T790M [124]. Heat shock protein inhibitors such a 
geldanamycin  or  17-DMAG  are  also  thought  to  be  a 
potent strategy against T790M [79]. 
novel biomarkers
Both primary and acquired resistance turn out to be 
quite  complex  biologically  and  generate  a  tremendous 
need for appropriate biomarkers both for treatment 
selection as well as monitoring. Novel platforms for the 
detection of circulating tumor cells and genetic changes in 
these tumor cells seem the most promising to fill this void. 
E.g. one study of CTCs from lung cancer patients was able 
to identify EGFR T790M in CTCs of some patients and 
progression-free survival was shorter as one might expect 
in patients with than without T790M on erlotinib [125]. 
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